Compare BXSL & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | GKOS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | N/A | 2015 |
| Metric | BXSL | GKOS |
|---|---|---|
| Price | $26.42 | $121.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $29.13 | ★ $130.93 |
| AVG Volume (30 Days) | ★ 1.8M | 728.9K |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $1,413,784,000.00 | $469,820,000.00 |
| Revenue This Year | $9.05 | $31.33 |
| Revenue Next Year | $0.48 | $24.01 |
| P/E Ratio | $10.04 | ★ N/A |
| Revenue Growth | 10.58 | ★ 30.38 |
| 52 Week Low | $24.85 | $73.16 |
| 52 Week High | $34.64 | $163.71 |
| Indicator | BXSL | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 61.92 |
| Support Level | $25.90 | $93.96 |
| Resistance Level | $26.94 | $130.23 |
| Average True Range (ATR) | 0.56 | 5.21 |
| MACD | 0.05 | 0.81 |
| Stochastic Oscillator | 62.61 | 77.20 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.